A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

Inclusion Criteria:

1. Male or female participants ≥18 years of age at Visit 1 (Day 1).

2. Participants who are willing and able to comply with all scheduled visits,investigational plan, laboratory tests, lifestyle considerations, and other studyprocedures.

3. Healthy participants who are determined by medical history, physical examination (ifrequired), and clinical judgment of the investigator to be eligible for inclusion inthe study.

4. Capable of giving signed informed consent as described in the protocol, whichincludes compliance with the requirements and restrictions listed in the ICD and inthis protocol.

Exclusion Criteria:

1. Medical or psychiatric condition, including recent (within the past year) or activesuicidal ideation/behavior or laboratory abnormality, that may increase the risk ofstudy participation or, in the investigator's judgment, make the participantinappropriate for the study.

2. History of severe adverse reaction associated with any vaccine and/or severeallergic reaction (eg, anaphylaxis) to any component of the study intervention(s).

3. Immunocompromised individuals with known or suspected immunodeficiency, asdetermined by history and/or laboratory/physical examination.

4. Bleeding diathesis or condition associated with prolonged bleeding that would, inthe opinion of the investigator, contraindicate intramuscular injection.

5. Allergy to egg proteins (egg or egg products) or chicken proteins.

6. Individuals who receive treatment with radiotherapy or immunosuppressive therapy,including cytotoxic agents or systemic corticosteroids (if systemic corticosteroidsare administered for ≥14 days at a dose of ≥20 mg/day of prednisone or equivalent),eg, for cancer or an autoimmune disease, or planned receipt throughout the study.Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes)corticosteroids are permitted.

7. Receipt of blood/plasma products or immunoglobulin from 60 days before studyintervention administration, or planned receipt throughout the study.

8. Vaccination with any investigational or licensed influenza vaccine within 6 months (175 days) before study intervention administration, or ongoing receipt of chronicantiviral therapy with activity against influenza.

9. Any participant who has received or plans to receive a modRNA-platform SARS CoV-2vaccine within 14 days before or after study vaccination at Visit 1.

10. Participation in other studies involving administration of a study interventionwithin 28 days prior to, and/or during, participation in this study.

11. Investigator site staff directly involved in the conduct of the study and theirfamily members, site staff otherwise supervised by the investigator, and sponsor andsponsor delegate employees directly involved in the conduct of the study and theirfamily members.